MX2021013132A - Metodos para la administracion de ciertos inhibidores del transportador 2 vesicular de monoaminas (vmat2). - Google Patents

Metodos para la administracion de ciertos inhibidores del transportador 2 vesicular de monoaminas (vmat2).

Info

Publication number
MX2021013132A
MX2021013132A MX2021013132A MX2021013132A MX2021013132A MX 2021013132 A MX2021013132 A MX 2021013132A MX 2021013132 A MX2021013132 A MX 2021013132A MX 2021013132 A MX2021013132 A MX 2021013132A MX 2021013132 A MX2021013132 A MX 2021013132A
Authority
MX
Mexico
Prior art keywords
administration
methods
vmat2 inhibitors
certain
certain vmat2
Prior art date
Application number
MX2021013132A
Other languages
English (en)
Inventor
Grace S Liang
Dao Tuyet Thai-Cuarto
Barbara Scholz
Eiry W Roberts
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of MX2021013132A publication Critical patent/MX2021013132A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporciona un método para administrar un inhibidor del transportador 2 vesicular de monoaminas (VMAT2) a un paciente que lo necesita, en donde el paciente experimenta uno o más signos o síntomas clínicamente significativos de tipo parkinsoniano.
MX2021013132A 2019-05-09 2020-05-08 Metodos para la administracion de ciertos inhibidores del transportador 2 vesicular de monoaminas (vmat2). MX2021013132A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962845599P 2019-05-09 2019-05-09
PCT/US2020/032188 WO2020227672A1 (en) 2019-05-09 2020-05-08 Methods for the administration of certain vmat2 inhibitors

Publications (1)

Publication Number Publication Date
MX2021013132A true MX2021013132A (es) 2021-11-25

Family

ID=70919120

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013132A MX2021013132A (es) 2019-05-09 2020-05-08 Metodos para la administracion de ciertos inhibidores del transportador 2 vesicular de monoaminas (vmat2).

Country Status (15)

Country Link
US (2) US20200397779A1 (es)
EP (1) EP3965764A1 (es)
JP (1) JP2022531696A (es)
KR (1) KR20220007105A (es)
CN (1) CN114340624A (es)
AU (1) AU2020270145A1 (es)
BR (1) BR112021020709A2 (es)
CA (1) CA3136466A1 (es)
EA (1) EA202193012A1 (es)
IL (1) IL287902A (es)
JO (1) JOP20210274A1 (es)
MA (1) MA55893A (es)
MX (1) MX2021013132A (es)
SG (1) SG11202111465RA (es)
WO (1) WO2020227672A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230038601A (ko) 2017-01-27 2023-03-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
EP3836926A4 (en) 2018-08-15 2022-05-04 Neurocrine Biosciences, Inc. METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
MX2023014827A (es) * 2021-06-30 2024-01-15 Neurocrine Biosciences Inc Valbenazina para usarse en el tratamiento complementario de la esquizofrenia.
IL310907A (en) 2021-08-20 2024-04-01 Neurocrine Biosciences Inc Screening methods for VMAT2 inhibitors
WO2023172849A1 (en) * 2022-03-07 2023-09-14 Neurocrine Biosciences, Inc. Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US952A (en) 1838-09-27 I antoni bengini
US10065A (en) 1853-10-04 Improvement in machines for topping cotton jn the field
KR20160147044A (ko) * 2014-05-06 2016-12-21 뉴로크린 바이오사이언시즈 인코퍼레이티드 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
US20190015396A1 (en) * 2015-06-23 2019-01-17 Neurocrine Biosciences, Inc. Vmat2 inhibitors for treating neurological diseases or disorders
KR20230038601A (ko) * 2017-01-27 2023-03-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
EP3836926A4 (en) * 2018-08-15 2022-05-04 Neurocrine Biosciences, Inc. METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS

Also Published As

Publication number Publication date
CN114340624A (zh) 2022-04-12
TW202108138A (zh) 2021-03-01
JP2022531696A (ja) 2022-07-08
EP3965764A1 (en) 2022-03-16
EA202193012A1 (ru) 2022-03-02
JOP20210274A1 (ar) 2023-01-30
AU2020270145A1 (en) 2021-12-23
SG11202111465RA (en) 2021-11-29
CA3136466A1 (en) 2020-11-12
BR112021020709A2 (pt) 2021-12-14
MA55893A (fr) 2022-03-16
WO2020227672A1 (en) 2020-11-12
US20200397779A1 (en) 2020-12-24
IL287902A (en) 2022-01-01
US20220040169A1 (en) 2022-02-10
KR20220007105A (ko) 2022-01-18

Similar Documents

Publication Publication Date Title
JOP20210274A1 (ar) طرق لإعطاء مثبط vmat2 معين
MX2022000559A (es) Metodos para la administracion de ciertos inhibidores de vmat2 a pacientes con insuficiencia renal grave.
PH12021550302A1 (en) Methods for the administration of certain vmat2 inhibitors
PH12019501732A1 (en) Methods for the administration of certain vmat2 inhibitors
PH12020550237A1 (en) Methods for the administration of certain vmat2 inhibitors
NO20060416L (no) Ny anvendelse I
CR20200553A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
EA200400966A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
RS52945B (en) PHARMACEUTICAL FORMULATIONS AND THEIR APPLICATION IN THE TREATMENT OF WOMEN SEXUAL DYSFUNCTION
CR9694A (es) Inhibidores de la transcriptasa reversa de vih
YU10101A (sh) Prolekovi inhibitori proton pumpe
AR119158A1 (es) Tratamientos de angioedema hereditario
CR20220199A (es) Inhibidores del factor d del complemento para administración oral
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
CL2022000889A1 (es) Inhibidores del factor d del complemento para administración oral
MX2023014827A (es) Valbenazina para usarse en el tratamiento complementario de la esquizofrenia.
MX2019005723A (es) Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo.
WO2021239928A3 (en) Treatment of cardiometabolic disease with inhibitors of type i interferon signalling
EA202190252A1 (ru) Способы введения определенных ингибиторов vmat2
MX2022001044A (es) Inhibidor de sglt2/dpp4 y su aplicacion.
JOP20210192A1 (ar) إكتشاف و تصميم مركبات جديدة لعلاج مرض فايروس كورونا المستجد لسنة 2019 (كوفيد-19)
UA86082U (ru) Способ лечения миопии
CO6390037A2 (es) Combinación antitumoral que asocia ave8062 y docetaxel
UA49089U (ru) Способ лечения острой сердечной недостаточности